These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15254048)

  • 1. Autologous dendritic cell vaccines for non-small-cell lung cancer.
    Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
    J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.
    Hirschowitz EA; Foody T; Hidalgo GE; Yannelli JR
    Lung Cancer; 2007 Sep; 57(3):365-72. PubMed ID: 17509725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
    J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
    Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
    Um SJ; Choi YJ; Shin HJ; Son CH; Park YS; Roh MS; Kim YS; Kim YD; Lee SK; Jung MH; Lee MK; Son C; Choi PJ; Chung J; Kang CD; Lee EY
    Lung Cancer; 2010 Nov; 70(2):188-94. PubMed ID: 20223553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC).
    Yannelli JR; Sturgill J; Foody T; Hirschowitz E
    Lung Cancer; 2005 Mar; 47(3):337-50. PubMed ID: 15713517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
    Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.
    Kvistborg P; Bechmann CM; Pedersen AW; Toh HC; Claesson MH; Zocca MB
    Vaccine; 2009 Dec; 28(2):542-7. PubMed ID: 19837091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
    Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
    J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small-cell lung cancer vaccine therapy: a concise review.
    O'Mahony D; Kummar S; Gutierrez ME
    J Clin Oncol; 2005 Dec; 23(35):9022-8. PubMed ID: 16219932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.